Insider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Purchases 83,334 Shares of Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels acquired 83,334 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $0.12 per share, with a total value of $10,000.08. Following the completion of the purchase, the chief executive officer now directly owns 1,764,029 shares in the company, valued at $211,683.48. The trade was a 4.96 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

AIM ImmunoTech Price Performance

Shares of NYSE AIM traded up $0.00 during midday trading on Tuesday, hitting $0.12. The stock had a trading volume of 1,145,808 shares, compared to its average volume of 495,243. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.24. The company has a market capitalization of $8.46 million, a PE ratio of -0.26 and a beta of -0.29. AIM ImmunoTech Inc. has a 1 year low of $0.11 and a 1 year high of $0.62.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lowered their price target on AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a research report on Tuesday, December 10th.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).